Prosthesis (i.e. – artificial body members) – parts thereof – or ai – Arterial prosthesis – Drug delivery
Reexamination Certificate
2000-03-13
2003-09-02
Willse, David H. (Department: 3738)
Prosthesis (i.e., artificial body members), parts thereof, or ai
Arterial prosthesis
Drug delivery
Reexamination Certificate
active
06613082
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to prostheses for implantation into a mammalian vessel, and in particular, to intraluminal stents that are provided with a cover that can deliver and release drugs.
2. Description of the Prior Art
The treatment of stenosis is the subject of much research and discussion. Stenosis are currently being treated by a number of well-known procedures, including balloon dilatation, stenting, ablation, atherectomy or laser treatment.
Restenosis is the renarrowing of a peripheral or coronary artery after trauma to that artery caused by efforts to open a stenosed portion of the artery, such as by balloon dilatation, ablation, atherectomy or laser treatment of the artery. For such procedures, restenosis occurs at a rate of about 20-50% depending on the definition, vessel location, lesion length and a number of other morphological and clinical variables. Restenosis is believed to be a natural healing reaction to the injury of the arterial wall that is caused by angioplasty procedures. The host reaction begins with the thrombotic mechanism at the site of the injury. The final result of the complex steps of the healing process can be intimal hyperplasia, the uncontrolled migration and proliferation of medial smooth muscle cells, combined with their extracellular matrix production, until the artery is again stenosed or occluded.
Many attempts have been made or suggested to treat stenosis, and to prevent or minimize restenosis. One common approach is to implant intravascular stents in coronary and peripheral vessels. The stent is usually inserted by a delivery system (e.g., such as a catheter) into a vascular lumen and expanded (either via a balloon on a catheter, or through self-expansion) into contact with the diseased portion of the arterial wall to provide mechanical support for the lumen. The positioning of stent in the lumen can be used to treat stenosis by re-opening the lumen that had been partially blocked by the stenosis. However, it has been found that restenosis can still occur with such stents in place. In addition, a stent itself can cause undesirable local thrombosis. To address the problem of thrombosis, persons receiving stents also receive extensive systemic treatment with anti-coagulant and antiplatelet drugs.
To address the restenosis problem, a number of approaches have been suggested. One type of approach relates to the delivery of drugs to minimize restenosis. As one example, these drugs can be delivered via oral, intravascular or intramuscular introduction, but these attempts have been largely unsuccessful. Unfortunately, pills and injections are known to be ineffective modes of administration because constant drug delivery and higher local concentration are very difficult to achieve via these means. Through repeated doses, these drugs often cycle through concentration peaks and valleys, resulting in time periods of toxicity and ineffectiveness.
Localized drug delivery is another example. There were many different attempts to provide localized drug delivery. One example of localized drug delivery is to provide the metallic walls or wires of the stents with therapeutic substances, fibrin and other drugs that can be released over a period of time at the diseased location of the vessel. However, the incorporation of drug into the walls or wires of the stent may significantly compromise the strength of the stent.
A second example of localized drug delivery is to incorporate a drug into a stent that is constructed not of metal but of a biodegradable polymer. However, the loading in and releasing of drugs from a polymeric stent may change the structural integrity and mechanical properties of the stent.
A third example of localized drug delivery is to directly coat the metal stent with a polymer that is bonded to or contains the desired drugs or anti-stenotic substances. Unfortunately, such polymer-coated stents have not been completely effective in preventing restenosis because of the cracking of the polymer as the stent is being expanded during deployment, saturation of the drug binding sites on the stent, and other reasons.
A fourth example of localized drug delivery is to provide a polymer sleeve or sheath that encompasses a portion of the stent. The sleeve or sheath would operate as a local drug delivery device. In some instances, the sheath or sleeve is made up of a bioabsorbable polymer that incorporates a drug, with the sheath or sleeve having a thickness to allow for controlled release of the drug. However, this approach suffers from the drawback that very few drugs are capable of being incorporated with common solid state polymers. In addition, directional release of drug to either the lumen or the arterial wall cannot be achieved. It will also be problematic for medical practitioners to select the type of drug and the dosage of the drug to be used, as well as the stent type to be implanted.
In addition to the problems of stenosis and restenosis, the development of cancerous blockages inside body passageways (e.g., esophagus, bile ducts, trachea, intestine, vasculature and urethra, among others) can also be treated with stents, which operate to hold open passageways which have been blocked by the cancerous growth or tumors. However, the stents do not prevent the ingrowth of the cancerous material through the interstices of the stent. If the ingrowth reaches the inside of the stent, it might result in blockage of the body passageway in which the stent had been implanted.
In addition to the above-described problems experienced by localized drug delivery, conventional stents are also ineffective in preventing the ingrowth of host tissue proliferation or inflammatory material through the interstices of the stent.
Thus, there still remains a need for a prosthesis that provides effective localized drug delivery to minimize or prevent restenosis and the ingrowth of host tissue proliferation or inflammatory material through the interstices of the stent, while avoiding the disadvantages set forth above.
SUMMARY OF THE DISCLOSURE
It is an object of the present invention to provide an intraluminal prosthesis that minimizes or prevents the ingrowth of host tissue proliferation or inflammatory material through the interstices or ends of a stent.
It is another object of the present invention to provide an intraluminal prosthesis that provides effective localized drug delivery.
In order to accomplish the objects of the present invention, there is provided a prosthesis having a cylindrical stent and a cover provided about the outer periphery of the stent. The cover can be made from a water absorbent material, and a matrix of protein. In one embodiment of the present invention, the cover is made from either tissue or hydrogel.
REFERENCES:
patent: 3657744 (1972-04-01), Ersek
patent: 3988782 (1976-11-01), Dardik et al.
patent: 4140126 (1979-02-01), Choudhury
patent: 4755593 (1988-07-01), Lauren
patent: 4925710 (1990-05-01), Buck et al.
patent: 5122154 (1992-06-01), Rhodes
patent: 5123917 (1992-06-01), Lee
patent: 5286254 (1994-02-01), Shapland et al.
patent: 5383928 (1995-01-01), Scott et al.
patent: 5389106 (1995-02-01), Tower
patent: 5411550 (1995-05-01), Herweck et al.
patent: 5466509 (1995-11-01), Kowligi et al.
patent: 5507771 (1996-04-01), Gianturco
patent: 5562697 (1996-10-01), Christiansen
patent: 5562728 (1996-10-01), Lazarus et al.
patent: 5578075 (1996-11-01), Dayton
patent: 5584877 (1996-12-01), Miyake et al.
patent: 5609629 (1997-03-01), Fearnot et al.
patent: 5616608 (1997-04-01), Kinsella et al.
patent: 5620763 (1997-04-01), House et al.
patent: 5628784 (1997-05-01), Strecker
patent: 5628788 (1997-05-01), Pinchuk
patent: 5637113 (1997-06-01), Tartaglia et al.
patent: 5674241 (1997-10-01), Bley et al.
patent: 5693085 (1997-12-01), Buirge et al.
patent: 5697967 (1997-12-01), Dinh et al.
patent: 5700285 (1997-12-01), Myers et al.
patent: 5700286 (1997-12-01), Tartaglia et al.
patent: 5707385 (1998-01-01), Williams
patent: 5709874 (1998-01-01), Hanson et al.
patent: 5718973 (1998-02-01), Le
Jackson Suzette J.
Sun Raymond
Willse David H.
LandOfFree
Stent having cover with drug delivery capability does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stent having cover with drug delivery capability, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stent having cover with drug delivery capability will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3057682